Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV.
Clinical progression
HIV-infection
Inflammation
Microbial translocation
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
12 Jun 2021
12 Jun 2021
Historique:
received:
22
01
2021
accepted:
28
05
2021
entrez:
12
6
2021
pubmed:
13
6
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Despite the effectiveness of cART, people living with HIV still experience an increased risk of serious non-AIDS events, as compared to the HIV negative population. Whether pre-cART microbial translocation (MT) and systemic inflammation might predict morbidity/mortality during suppressive cART, independently of other known risk factors, is still unclear. Thus, we aimed to investigate the role of pre-cART inflammation and MT as predictors of clinical progression in HIV+ patients enrolled in the Icona Foundation Study Cohort. We included Icona patients with ≥2 vials of plasma stored within 6 months before cART initiation and at least one CD4 count after therapy available. Circulating biomarker: LPS, sCD14, EndoCab, hs-CRP. Kaplan-Meier curves and Cox regression models were used. We defined the endpoint of clinical progression as the occurrence of a new AIDS-defining condition, severe non-AIDS condition (SNAEs) or death whichever occurred first. Follow-up accrued from the data of starting cART and was censored at the time of last available clinical visit. Biomarkers were evaluated as both binary (above/below median) and continuous variables (logescale). We studied 486 patients with 125 clinical events: 39 (31%) AIDS, 66 (53%) SNAEs and 20 (16%) deaths. Among the analyzed MT and pro-inflammatory markers, hs-CRP seemed to be the only biomarker retaining some association with the endpoint of clinical progression (i.e. AIDS/SNAEs/death) after adjustment for confounders, both when the study population was stratified according to the median of the distribution (1.51 mg/L) and when the study population was stratified according to the 33% percentiles of the distribution (low 0.0-1.1 mg/L; intermediate 1.2-5.3 mg/L; high > 5.3 mg/L). In particular, the higher the hs-CRP values, the higher the risk of clinical progression (p = 0.056 for median-based model; p = 0.002 for 33% percentile-based model). Our data carries evidence for an association between the risk of disease progression after cART initiation and circulating pre-cART hs-CRP levels but not with levels of MT. These results suggest that pre-therapy HIV-driven pro-inflammatory milieu might overweight MT and its downstream immune-activation.
Sections du résumé
BACKGROUND
BACKGROUND
Despite the effectiveness of cART, people living with HIV still experience an increased risk of serious non-AIDS events, as compared to the HIV negative population. Whether pre-cART microbial translocation (MT) and systemic inflammation might predict morbidity/mortality during suppressive cART, independently of other known risk factors, is still unclear. Thus, we aimed to investigate the role of pre-cART inflammation and MT as predictors of clinical progression in HIV+ patients enrolled in the Icona Foundation Study Cohort.
METHODS
METHODS
We included Icona patients with ≥2 vials of plasma stored within 6 months before cART initiation and at least one CD4 count after therapy available. Circulating biomarker: LPS, sCD14, EndoCab, hs-CRP. Kaplan-Meier curves and Cox regression models were used. We defined the endpoint of clinical progression as the occurrence of a new AIDS-defining condition, severe non-AIDS condition (SNAEs) or death whichever occurred first. Follow-up accrued from the data of starting cART and was censored at the time of last available clinical visit. Biomarkers were evaluated as both binary (above/below median) and continuous variables (logescale).
RESULTS
RESULTS
We studied 486 patients with 125 clinical events: 39 (31%) AIDS, 66 (53%) SNAEs and 20 (16%) deaths. Among the analyzed MT and pro-inflammatory markers, hs-CRP seemed to be the only biomarker retaining some association with the endpoint of clinical progression (i.e. AIDS/SNAEs/death) after adjustment for confounders, both when the study population was stratified according to the median of the distribution (1.51 mg/L) and when the study population was stratified according to the 33% percentiles of the distribution (low 0.0-1.1 mg/L; intermediate 1.2-5.3 mg/L; high > 5.3 mg/L). In particular, the higher the hs-CRP values, the higher the risk of clinical progression (p = 0.056 for median-based model; p = 0.002 for 33% percentile-based model).
CONCLUSIONS
CONCLUSIONS
Our data carries evidence for an association between the risk of disease progression after cART initiation and circulating pre-cART hs-CRP levels but not with levels of MT. These results suggest that pre-therapy HIV-driven pro-inflammatory milieu might overweight MT and its downstream immune-activation.
Identifiants
pubmed: 34116650
doi: 10.1186/s12879-021-06260-y
pii: 10.1186/s12879-021-06260-y
pmc: PMC8196504
doi:
Substances chimiques
Anti-Retroviral Agents
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
557Commentaires et corrections
Type : ErratumIn
Références
Connick E, Lederman MM, Kotzin BL, Spritzler J, Kuritzkes DR, St Clair M, et al. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis. 2000;181(1):358–63. https://doi.org/10.1086/315171 .
doi: 10.1086/315171
pubmed: 10608789
Guihot A, Bourgarit A, Carcelain G, Autran B. Immune reconstitution after a decade of combined antiretroviral therapies for human immunodeficiency virus. Trends Immunol. 2011;32(3):131–7. https://doi.org/10.1016/j.it.2010.12.002 .
doi: 10.1016/j.it.2010.12.002
pubmed: 21317040
Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet. 1998;351(9117):1682–6. https://doi.org/10.1016/S0140-6736(97)10291-4 .
doi: 10.1016/S0140-6736(97)10291-4
pubmed: 9734884
Marcus JL, Chao CR, Leyden WA, Xu L, Quesenberry CP Jr, Klein DB, et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr. 2016;73(1):39–46. https://doi.org/10.1097/QAI.0000000000001014 .
doi: 10.1097/QAI.0000000000001014
pubmed: 27028501
pmcid: 5427712
Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, et al. Projected life expectancy of people with HIV according to timing of diagnosis. Aids. 2012;26(3):335–43. https://doi.org/10.1097/QAD.0b013e32834dcec9 .
doi: 10.1097/QAD.0b013e32834dcec9
pubmed: 22089374
Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017;18(4):256–66. https://doi.org/10.1111/hiv.12421 .
doi: 10.1111/hiv.12421
pubmed: 27578404
Hsu DC, Sereti I. Serious non-AIDS events: therapeutic targets of immune activation and chronic inflammation in HIV infection. Drugs. 2016;76(5):533–49. https://doi.org/10.1007/s40265-016-0546-7 .
doi: 10.1007/s40265-016-0546-7
pubmed: 26915027
pmcid: 5578711
Mutoh Y, Nishijima T, Inaba Y, Tanaka N, Kikuchi Y, Gatanaga H, et al. Incomplete recovery of CD4 cell count, CD4 percentage, and CD4/CD8 ratio in patients with human immunodeficiency virus infection and suppressed viremia during long-term antiretroviral therapy. Clin Infect Dis. 2018;67(6):927–33. https://doi.org/10.1093/cid/ciy176 .
doi: 10.1093/cid/ciy176
pubmed: 29509894
Zoufaly A, Cozzi-Lepri A, Reekie J, Kirk O, Lundgren J, Reiss P, et al. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. PLoS One. 2014;9(1):e87160. https://doi.org/10.1371/journal.pone.0087160 .
doi: 10.1371/journal.pone.0087160
pubmed: 24498036
pmcid: 3909048
Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, Kaslow RA, et al. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(5):553–8. https://doi.org/10.1097/QAI.0b013e31816856c5 .
doi: 10.1097/QAI.0b013e31816856c5
pubmed: 18285713
Lapadula G, Cozzi-Lepri A, Marchetti G, Antinori A, Chiodera A, Nicastri E, et al. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. AIDS. 2013;27(5):769–79. https://doi.org/10.1097/QAD.0b013e32835cb747 .
doi: 10.1097/QAD.0b013e32835cb747
pubmed: 23719349
Loutfy MR, Genebat M, Moore D, Raboud J, Chan K, Antoniou T, et al. A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression. J Acquir Immune Defic Syndr. 2010;55(4):451–9. https://doi.org/10.1097/QAI.0b013e3181ec28ff .
doi: 10.1097/QAI.0b013e3181ec28ff
pubmed: 21105259
IeDEA and COHERE Cohort Collaborations. Global trends in CD4 cell count at the start of antiretroviral therapy: collaborative study of treatment programs. Clin Infect Dis. 2018;66(6):893–903.
doi: 10.1093/cid/cix915
Saison J, Ferry T, Demaret J, Maucort-Boulch D, Venet F, Perpoint T, et al. Relationship between discordant response to HAART, Tregs, immune activation and low-level viraemia. J Int AIDS Soc. 2014;17(4 Suppl 3):19672. https://doi.org/10.7448/IAS.17.4.19672 .
doi: 10.7448/IAS.17.4.19672
pubmed: 25397422
pmcid: 4225367
Anthony KB, Yoder C, Metcalf JA, DerSimonian R, Orenstein JM, Stevens RA, et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr. 2003;33(2):125–33. https://doi.org/10.1097/00126334-200306010-00002 .
doi: 10.1097/00126334-200306010-00002
pubmed: 12794543
Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, Ignacio CC, et al. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA. J Infect Dis. 2006;194(1):29–37. https://doi.org/10.1086/504718 .
doi: 10.1086/504718
pubmed: 16741879
Massanella M, Negredo E, Perez-Alvarez N, Puig J, Ruiz-Hernandez R, Bofill M, et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS. 2010;24(7):959–68. https://doi.org/10.1097/QAD.0b013e328337b957 .
doi: 10.1097/QAD.0b013e328337b957
pubmed: 20177358
Borges AH, Silverberg MJ, Wentworth D, Grulich AE, Fatkenheuer G, Mitsuyasu R, et al. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. Aids. 2013;27(9):1433–41. https://doi.org/10.1097/QAD.0b013e32835f6b0c .
doi: 10.1097/QAD.0b013e32835f6b0c
pubmed: 23945504
Ford ES, Greenwald JH, Richterman AG, Rupert A, Dutcher L, Badralmaa Y, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. Aids. 2010;24(10):1509–17. https://doi.org/10.1097/QAD.0b013e32833ad914 .
doi: 10.1097/QAD.0b013e32833ad914
pubmed: 20505494
Tien PC, Choi AI, Zolopa AR, Benson C, Tracy R, Scherzer R, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr. 2010;55(3):316–22. https://doi.org/10.1097/QAI.0b013e3181e66216 .
doi: 10.1097/QAI.0b013e3181e66216
pubmed: 20581689
pmcid: 2955817
Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203. https://doi.org/10.1371/journal.pmed.0050203 .
doi: 10.1371/journal.pmed.0050203
pubmed: 18942885
pmcid: 2570418
Balagopal A, Asmuth DM, Yang WT, Campbell TB, Gupte N, Smeaton L, et al. Pre-cART elevation of CRP and CD4+ T-cell immune activation associated with HIV clinical progression in a multinational case-cohort study. J Acquir Immune Defic Syndr. 2015;70(2):163–71. https://doi.org/10.1097/QAI.0000000000000696 .
doi: 10.1097/QAI.0000000000000696
pubmed: 26017661
pmcid: 4573329
Marchetti G, Cozzi-Lepri A, Merlini E, Bellistrì GM, Castagna A, Galli M, et al. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS. 2011;25(11):1385–94. https://doi.org/10.1097/QAD.0b013e3283471d10 .
doi: 10.1097/QAD.0b013e3283471d10
pubmed: 21505312
Leon A, Leal L, Torres B, Lucero C, Inciarte A, Arnedo M, et al. Association of microbial translocation biomarkers with clinical outcome in controllers HIV-infected patients. Aids. 2015;29(6):675–81. https://doi.org/10.1097/QAD.0000000000000596 .
doi: 10.1097/QAD.0000000000000596
pubmed: 25849831
Vassallo M, Mercié P, Cottalorda J, Ticchioni M, Dellamonica P. The role of lipopolysaccharide as a marker of immune activation in HIV-1 infected patients: a systematic literature review. Virol J. 2012;9(1):174. https://doi.org/10.1186/1743-422X-9-174 .
doi: 10.1186/1743-422X-9-174
pubmed: 22925532
pmcid: 3495848
Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12(12):1365–71. https://doi.org/10.1038/nm1511 .
doi: 10.1038/nm1511
pubmed: 17115046
Marchetti G, Bellistri GM, Borghi E, Tincati C, Ferramosca S, La Francesca M, et al. Microbial translocation is associated with sustained failure in CD4+ T-cell reconstitution in HIV-infected patients on long-term highly active antiretroviral therapy. AIDS. 2008;22(15):2035–8. https://doi.org/10.1097/QAD.0b013e3283112d29 .
doi: 10.1097/QAD.0b013e3283112d29
pubmed: 18784466
Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009;199(8):1177–85. https://doi.org/10.1086/597476 .
doi: 10.1086/597476
pubmed: 19265479
Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210(8):1228–38. https://doi.org/10.1093/infdis/jiu238 .
doi: 10.1093/infdis/jiu238
pubmed: 24755434
pmcid: 4192038
Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210(8):1248–59. https://doi.org/10.1093/infdis/jiu254 .
doi: 10.1093/infdis/jiu254
pubmed: 24795473
pmcid: 4192039
Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. A trial of early Antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22. https://doi.org/10.1056/NEJMoa1507198 .
doi: 10.1056/NEJMoa1507198
pubmed: 26193126
Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807. https://doi.org/10.1056/NEJMoa1506816 .
doi: 10.1056/NEJMoa1506816
pubmed: 26192873
Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, Emenyonu N, et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. Aids. 2011;25(17):2123–31. https://doi.org/10.1097/QAD.0b013e32834c4ac1 .
doi: 10.1097/QAD.0b013e32834c4ac1
pubmed: 21881481
Lee SA, Mefford JA, Huang Y, Witte JS, Martin JN, Haas DW, et al. Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans. Aids. 2016;30(11):1807–15. https://doi.org/10.1097/QAD.0000000000001124 .
doi: 10.1097/QAD.0000000000001124
pubmed: 27088321
Byakwaga H, Boum Y 2nd, Huang Y, Muzoora C, Kembabazi A, Weiser SD, et al. The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. J Infect Dis. 2014;210(3):383–91. https://doi.org/10.1093/infdis/jiu115 .
doi: 10.1093/infdis/jiu115
pubmed: 24585899
pmcid: 4148610
Siedner MJ, Bwana MB, Asiimwe S, Musinguzi N, Castillo-Mancilla J, Amanyire G, et al. Inflammatory biomarkers prior to antiretroviral therapy as prognostic markers of 12-month mortality in South Africa and Uganda. Aids. 2019;33(13):2043–8. https://doi.org/10.1097/QAD.0000000000002305 .
doi: 10.1097/QAD.0000000000002305
pubmed: 31274541
d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.a. study group. Italian cohort of antiretroviral-naive patients. Aids. 2000;14(5):499–507. https://doi.org/10.1097/00002030-200003310-00005 .
doi: 10.1097/00002030-200003310-00005
pubmed: 10780712
Gnauck A, Lentle RG, Kruger MC. Chasing a ghost?--issues with the determination of circulating levels of endotoxin in human blood. Crit Rev Clin Lab Sci. 2016;53(3):197–215. https://doi.org/10.3109/10408363.2015.1123215 .
doi: 10.3109/10408363.2015.1123215
pubmed: 26732012
Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50(10):1387–96.
doi: 10.1086/652283
Hunt PW, Lee SA, Siedner MJ. Immunologic biomarkers, morbidity, and mortality in treated HIV infection. J Infect Dis. 2016;214(Suppl 2):S44–50. https://doi.org/10.1093/infdis/jiw275 .
doi: 10.1093/infdis/jiw275
pubmed: 27625430
pmcid: 5021241
Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, et al. Relevance of Interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy. PLoS One. 2016;11(5):e0155100. https://doi.org/10.1371/journal.pone.0155100 .
doi: 10.1371/journal.pone.0155100
pubmed: 27171281
pmcid: 4865234
Westhorpe CL, Schneider HG, Dunne M, Middleton T, Sundararajan V, Spelman T, et al. C-reactive protein as a predictor of cardiovascular risk in HIV-infected individuals. Sex Health. 2014;11(6):580–2. https://doi.org/10.1071/SH14130 .
doi: 10.1071/SH14130
pubmed: 25435195
Mora S, Ridker PM. Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006;97(2a):33a–41a.
doi: 10.1016/j.amjcard.2005.11.014
Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780–90. https://doi.org/10.1093/infdis/jiq118 .
doi: 10.1093/infdis/jiq118
pubmed: 21252259
pmcid: 3071127
Sandler N, Wand H, Nixon D, Perdersen C, Ruxrungtham K, Deeks S, et al. Plasma Levels of Soluble CD14 Predict Mortality in HIV Infection. San Francisco: CROI; 2010.
Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, French MA, et al. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011;203(11):1637–46. https://doi.org/10.1093/infdis/jir134 .
doi: 10.1093/infdis/jir134
pubmed: 21592994
pmcid: 3096784
Ouyang J, Isnard S, Lin J, Fombuena B, Chatterjee D, Wiche Salinas TR, et al. Daily variations of gut microbial translocation markers in ART-treated HIV-infected people. AIDS Res Ther. 2020;17(1):15. https://doi.org/10.1186/s12981-020-00273-4 .
doi: 10.1186/s12981-020-00273-4
pubmed: 32398104
pmcid: 7216536
Ramendra R, Isnard S, Mehraj V, Chen J, Zhang Y, Finkelman M, et al. Circulating LPS and (1→3)-β-D-glucan: a Folie à Deux contributing to HIV-associated immune activation. Front Immunol. 2019;10:465. https://doi.org/10.3389/fimmu.2019.00465 .
doi: 10.3389/fimmu.2019.00465
pubmed: 30967860
pmcid: 6430738
Mehraj V, Ramendra R, Isnard S, Dupuy FP, Ponte R, Chen J, et al. Circulating (1→3)-β-D-glucan is associated with immune activation during human immunodeficiency virus infection. Clin Infect Dis. 2020;70(2):232–41. https://doi.org/10.1093/cid/ciz212 .
doi: 10.1093/cid/ciz212
pubmed: 30877304